[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Institute of All Medicines\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,66],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100602492",false,"NCT07124208","RCT to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes","A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes","Inclusion Criteria:\n\n* Willing and able to give informed consent for participation in the trial.\n* Is able and willing to comply with all trial requirements.\n* Male or female aged 18-70 years old without major diseases.\n* An adult clinically diagnosed with DM2\n* Participants must not be heavy users of Tesla BioHealing devices; enrollment will be determined by the clinical team based on an evaluation of the participant's prior device usage.\n* Must be fluent in English.\n\nExclusion Criteria:\n\n* Untreated psychiatric disturbances that would affect trial participation as judged by research medical professionals.\n* Is participating in another investigational drug or device trial","ALL","18 Years","70 Years",{"count":19,"type":20},46,"ESTIMATED","INTERVENTIONAL",[23],"NA","Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can treat diabetes.\n\nStudy Design This is a randomized, double-blind, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in treating diabetes. Approximately 46 volunteers will participate in the study.\n\nStudy Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. This phase lasts for 4 weeks. At the end of Week 4, the active devices will replace the placebo. Both groups will be actively participating in the study for 2 months (8 weeks).\n\nOther than the Informed Consent Form (ICF), all study information will be recorded by using the subject number.\n\nThe Principal Investigator, study physicians, study nurses, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.\n\nStudy Enrollment Each potentially qualified volunteer will review the Informed Consent Form online (e-ICF) and Enrollment Criteria online (e-Criteria) first, then discuss the e-ICF and e-Criteria with the study team medical professional via telephone during the scheduled time. Each qualified volunteer will sign the e-ICF and send it to the Medical Office Coordinator. The study coordinator will assign the qualified volunteer a randomized subject number, then the volunteer will become a study participant.",[26],"Type 2 Diabetes",[28],"Diabetes, Biophotons, Ageing Marker, Stem Cells,","NOT_YET_RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-26","ACTUAL",{"date":35,"type":20},"2026-06-08",{"date":37,"type":20},"2027-08-15",{"name":39,"class":40},"First Institute of All Medicines","OTHER",2,{"id":43,"slug":4,"hasResults":10,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100586410","NCT06915012","Impact of Biophoton Therapy on Chronic Severe Arthritis Pain","A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Impact of Biophoton Therapy on Chronic Severe Arthritis Pain","Severe Pain","Inclusion Criteria:\n\n* Willing and able to give informed consent for participation in the trial.\n* Is able and willing to comply with all trial requirements.\n* Male or female aged 18-80 years old with chronic severe arthritis pain.\n* ≥3 months duration of chronic severe arthritis pain.\n* a current VAS pain rating ≥5\u002F10.\n* Able to complete the treatment for the study period.\n* Must be fluent in English.\n\nExclusion Criteria:\n\n* Untreated psychiatric disturbances that would affect trial participation as judged by the Caregiver or by the clinical study medical professional\n* Who relies on ventilators\n* Who had deep brain stimulators, or pacemakers, or implantable electronic devices\n* Co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, or any end-of-life prognosis.\n* Is participating in another investigational drug or device trial\n* Has an active infectious disease, such as COVID-19\n* Pregnant women.","80 Years",{"count":51,"type":20},102,[23],"Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can alleviate chronic severe pain.\n\nStudy Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in managing chronic severe pain. Approximately 102 patients with chronic severe arthritis pain will participate in the study.\n\nStudy Randomization The biostatistician will prepare a randomization schedule including a series of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group.\n\nOther than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants (and caregivers), will be blinded about who received which product during the first two weeks of study participation.\n\nStudy Enrollment Each potentially qualified patient will review the Informed Consent Form online (e-ICF) and Enrollment Criteria online (e-Criteria) first, then discuss the e-ICF and e-Criteria with the study team medical professional via telephone during the scheduled time. Each qualified patient will sign the e-ICF and send it to the Study Coordinator. The Study Coordinator will assign the qualified patient a randomized subject number, then the patient will become a study participant.\n\nStudy Procedure We expect that the participant will stay in this clinical treatment for 12 weeks, or 12 weeks if the participants are randomly placed in a placebo group. The 12 weeks of participation are double-blinded to record the placebo effects, as each set of the study device is labelled with a unique code for use by only one participant. The change of the placebo device to the treatment device will be performed by the study device management team staff, who will not inform the study participant or study research staff who are involved in study data collection. Each participant assigned to the Control Group will be treated with the 4 placebo devices on the bed. Each participant assigned to the Treatment Group will receive 4 Biophoton generator devices and placed on the bed on each side of the body. Each participant will use the Treatment or Control device for at least 8 hours every night for the 12 weeks during sleep. During the day, participants are welcome to bring the study devices and place them near the bodies during the daytime. At the end of the initial 12 weeks, study participants randomized to the Placebo group will be advised whether they will use the Open-Labeled product to treat them for 4 to 12 weeks. Only the visual analog scale of the pain data will be collected after the switch. Each participant will be guided by study team staff to perform the following tests on their assigned testing days: a visual analog scale, brief pain inventory, pain disability index, the standard SF-36 questionnaires (SF-36) for measuring life quality, the Pittsburgh Sleep Quality Index, a Patient Global Impression of Change, a Hospital Anxiety and Depression Scale, and inflammatory markers that provide objective evidence of inflammation.\n\nInvestigational Product and Mode of Administration Tesla BioHealing Biophotonizer is an over-the-counter (OTC) medical device, and it can be used by anyone who wants to increase blood circulation and reduce bodily pains. For this study, the active or inactive Biophotonizer will be labeled with a code. The participant and\u002For caregiver cannot know if the devices are active or inactive. When the participant places the devices close to the body, she\u002Fhe may or may not receive life force energy. The participant will record changes in quality of life and complete the standard study questionnaires at baseline and the end of each 2-week interval.\n\nComparator and Mode of Administration Clinical measurements will be conducted by medical professionals. The same shape, size, and weight of the device without generating biophotons is to be labeled with a random code and used as a comparator. The comparator device will be placed close to the body during sleep during the entire study period. The participant will record the life quality changes and answer the standard study questionnaires. Clinical measurements will be conducted by medical professionals.\n\nStudy Duration Estimated date of the first patient enrolled: November 15, 2024. The estimated date of the last patient completed: November 15, 2025.\n\nParticipants in the Treatment Group and Control Group will actively participate in the study for 12 or 24 weeks. Each Participant will answer the standard study questionnaires several times, respectively, at the baseline, at the end of each 2-week interval after starting the study treatment.",[55],"Arthritis","RECRUITING","2026-05-20",{"date":59,"type":33},"2026-05-22",{"date":61,"type":33},"2025-03-28",{"date":63,"type":20},"2026-12-31",{"name":39,"class":40},1,{"id":67,"slug":4,"hasResults":10,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":65},"100527456","NCT06147999","Impact of a Biophoton Therapy on Patients With Brain Disorders","Alzheimer","Inclusion Criteria:\n\n* Must meet conditions for approval.\n* Must be 18-years or older and stay in a hotel.\n* Must have a caregiver willing to support the participant's full involvement in the study. • The caregiver can assist in completing all study surveys.\n* Can provide informed consent or can be assisted by caregiver.\n* Can provide a clinical diagnosis of a brain disorder.\n* Can complete all study procedures during the study.\n* Must be fluent in English (or the Caregiver can fully translate).\n* Women of childbearing age must provide results of a pregnancy test in order to participate.\n\nExclusion Criteria:\n\n* Any untreated mental illnesses, that would affect study participation. This will be judged by the caregiver, or by the clinical study medical expert.\n* Someone that relies on a ventilator.\n* Someone who has a deep brain stimulator, pacemaker, or any implanted electronic devices.\n* Co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, or any end-of-life prognosis.\n* Is participating in another investigational drug or device trial.\n* Has an active infectious disease, such as COVID-19.\n* Pregnant women.",{"count":73,"type":20},80,[23],"Previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with Alzheimer's disease, dementia, stroke, traumatic brain injury, or Parkinson's disease. The current study is to confirm the previous clinical observation by conducting as a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. About 80 patients with brain disorder (Alzheimer's disease, dementia, stroke, traumatic brain injury, Parkinson's disease) will participate in the intervention clinical study at the Tesla MedBed Center located in Butler, PA.",[77],"Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury",[79,80,81,82],"Alzheimer's Disease, and\u002For","dementia, and\u002For","Parkinson's Disease, and\u002For","Traumatic Brain Injury, and\u002For","2025-08-04",{"date":85,"type":33},"2025-08-08",{"date":87,"type":33},"2023-11-08",{"date":89,"type":20},"2026-11-08",{"name":39,"class":40},""]